Cargando…

IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2

Disrupting inositol 1,4,5-trisphosphate (IP(3)) receptor (IP(3)R)/B-cell lymphoma 2 (Bcl-2) complexes using a cell-permeable peptide (stabilized TAT-fused IP(3)R-derived peptide (TAT-IDP(S))) that selectively targets the BH4 domain of Bcl-2 but not that of B-cell lymphoma 2-extra large (Bcl-Xl) pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Akl, H, Monaco, G, La Rovere, R, Welkenhuyzen, K, Kiviluoto, S, Vervliet, T, Molgó, J, Distelhorst, C W, Missiaen, L, Mikoshiba, K, Parys, J B, De Smedt, H, Bultynck, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674349/
https://www.ncbi.nlm.nih.gov/pubmed/23681227
http://dx.doi.org/10.1038/cddis.2013.140
_version_ 1782272357529812992
author Akl, H
Monaco, G
La Rovere, R
Welkenhuyzen, K
Kiviluoto, S
Vervliet, T
Molgó, J
Distelhorst, C W
Missiaen, L
Mikoshiba, K
Parys, J B
De Smedt, H
Bultynck, G
author_facet Akl, H
Monaco, G
La Rovere, R
Welkenhuyzen, K
Kiviluoto, S
Vervliet, T
Molgó, J
Distelhorst, C W
Missiaen, L
Mikoshiba, K
Parys, J B
De Smedt, H
Bultynck, G
author_sort Akl, H
collection PubMed
description Disrupting inositol 1,4,5-trisphosphate (IP(3)) receptor (IP(3)R)/B-cell lymphoma 2 (Bcl-2) complexes using a cell-permeable peptide (stabilized TAT-fused IP(3)R-derived peptide (TAT-IDP(S))) that selectively targets the BH4 domain of Bcl-2 but not that of B-cell lymphoma 2-extra large (Bcl-Xl) potentiated pro-apoptotic Ca(2+) signaling in chronic lymphocytic leukemia cells. However, the molecular mechanisms rendering cancer cells but not normal cells particularly sensitive to disrupting IP(3)R/Bcl-2 complexes are poorly understood. Therefore, we studied the effect of TAT-IDP(S) in a more heterogeneous Bcl-2-dependent cancer model using a set of ‘primed to death' diffuse large B-cell lymphoma (DL-BCL) cell lines containing elevated Bcl-2 levels. We discovered a large heterogeneity in the apoptotic responses of these cells to TAT-IDP(S) with SU-DHL-4 being most sensitive and OCI-LY-1 being most resistant. This sensitivity strongly correlated with the ability of TAT-IDP(S) to promote IP(3)R-mediated Ca(2+) release. Although total IP(3)R-expression levels were very similar among SU-DHL-4 and OCI-LY-1, we discovered that the IP(3)R2-protein level was the highest for SU-DHL-4 and the lowest for OCI-LY-1. Strikingly, TAT-IDP(S)-induced Ca(2+) rise and apoptosis in the different DL-BCL cell lines strongly correlated with their IP(3)R2-protein level, but not with IP(3)R1-, IP(3)R3- or total IP(3)R-expression levels. Inhibiting or knocking down IP(3)R2 activity in SU-DHL-4-reduced TAT-IDP(S)-induced apoptosis, which is compatible with its ability to dissociate Bcl-2 from IP(3)R2 and to promote IP(3)-induced pro-apoptotic Ca(2+) signaling. Thus, certain chronically activated B-cell lymphoma cells are addicted to high Bcl-2 levels for their survival not only to neutralize pro-apoptotic Bcl-2-family members but also to suppress IP(3)R hyperactivity. In particular, cancer cells expressing high levels of IP(3)R2 are addicted to IP(3)R/Bcl-2 complex formation and disruption of these complexes using peptide tools results in pro-apoptotic Ca(2+) signaling and cell death.
format Online
Article
Text
id pubmed-3674349
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36743492013-06-06 IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2 Akl, H Monaco, G La Rovere, R Welkenhuyzen, K Kiviluoto, S Vervliet, T Molgó, J Distelhorst, C W Missiaen, L Mikoshiba, K Parys, J B De Smedt, H Bultynck, G Cell Death Dis Original Article Disrupting inositol 1,4,5-trisphosphate (IP(3)) receptor (IP(3)R)/B-cell lymphoma 2 (Bcl-2) complexes using a cell-permeable peptide (stabilized TAT-fused IP(3)R-derived peptide (TAT-IDP(S))) that selectively targets the BH4 domain of Bcl-2 but not that of B-cell lymphoma 2-extra large (Bcl-Xl) potentiated pro-apoptotic Ca(2+) signaling in chronic lymphocytic leukemia cells. However, the molecular mechanisms rendering cancer cells but not normal cells particularly sensitive to disrupting IP(3)R/Bcl-2 complexes are poorly understood. Therefore, we studied the effect of TAT-IDP(S) in a more heterogeneous Bcl-2-dependent cancer model using a set of ‘primed to death' diffuse large B-cell lymphoma (DL-BCL) cell lines containing elevated Bcl-2 levels. We discovered a large heterogeneity in the apoptotic responses of these cells to TAT-IDP(S) with SU-DHL-4 being most sensitive and OCI-LY-1 being most resistant. This sensitivity strongly correlated with the ability of TAT-IDP(S) to promote IP(3)R-mediated Ca(2+) release. Although total IP(3)R-expression levels were very similar among SU-DHL-4 and OCI-LY-1, we discovered that the IP(3)R2-protein level was the highest for SU-DHL-4 and the lowest for OCI-LY-1. Strikingly, TAT-IDP(S)-induced Ca(2+) rise and apoptosis in the different DL-BCL cell lines strongly correlated with their IP(3)R2-protein level, but not with IP(3)R1-, IP(3)R3- or total IP(3)R-expression levels. Inhibiting or knocking down IP(3)R2 activity in SU-DHL-4-reduced TAT-IDP(S)-induced apoptosis, which is compatible with its ability to dissociate Bcl-2 from IP(3)R2 and to promote IP(3)-induced pro-apoptotic Ca(2+) signaling. Thus, certain chronically activated B-cell lymphoma cells are addicted to high Bcl-2 levels for their survival not only to neutralize pro-apoptotic Bcl-2-family members but also to suppress IP(3)R hyperactivity. In particular, cancer cells expressing high levels of IP(3)R2 are addicted to IP(3)R/Bcl-2 complex formation and disruption of these complexes using peptide tools results in pro-apoptotic Ca(2+) signaling and cell death. Nature Publishing Group 2013-05 2013-05-16 /pmc/articles/PMC3674349/ /pubmed/23681227 http://dx.doi.org/10.1038/cddis.2013.140 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by/3.0/ This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Original Article
Akl, H
Monaco, G
La Rovere, R
Welkenhuyzen, K
Kiviluoto, S
Vervliet, T
Molgó, J
Distelhorst, C W
Missiaen, L
Mikoshiba, K
Parys, J B
De Smedt, H
Bultynck, G
IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2
title IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2
title_full IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2
title_fullStr IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2
title_full_unstemmed IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2
title_short IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2
title_sort ip(3)r2 levels dictate the apoptotic sensitivity of diffuse large b-cell lymphoma cells to an ip(3)r-derived peptide targeting the bh4 domain of bcl-2
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674349/
https://www.ncbi.nlm.nih.gov/pubmed/23681227
http://dx.doi.org/10.1038/cddis.2013.140
work_keys_str_mv AT aklh ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT monacog ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT laroverer ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT welkenhuyzenk ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT kiviluotos ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT vervliett ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT molgoj ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT distelhorstcw ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT missiaenl ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT mikoshibak ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT parysjb ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT desmedth ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2
AT bultynckg ip3r2levelsdictatetheapoptoticsensitivityofdiffuselargebcelllymphomacellstoanip3rderivedpeptidetargetingthebh4domainofbcl2